Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Christine Tardell"'
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42598 (2012)
Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechan
Externí odkaz:
https://doaj.org/article/f977105d31fa4f8f9f44e379c7007545
Autor:
Lyubomir T. Vassilev, Binh Vu, Peter Wovkulich, Frank Podlaski, Michael Linn, Kwong-Him To, Kenneth Kolinsky, Edmund Lee, Rosario Garrido, Christine Tardell, Brian Higgins Mingxuan Xia, Zoran Filipovic, Kathryn Packman, Bradford Graves, Christian Tovar
PDF file - 71K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c1e12a2827bef15e4c7f52b8f26d01a
https://doi.org/10.1158/0008-5472.22398773.v1
https://doi.org/10.1158/0008-5472.22398773.v1
Autor:
Lyubomir T. Vassilev, Binh Vu, Peter Wovkulich, Frank Podlaski, Michael Linn, Kwong-Him To, Kenneth Kolinsky, Edmund Lee, Rosario Garrido, Christine Tardell, Brian Higgins Mingxuan Xia, Zoran Filipovic, Kathryn Packman, Bradford Graves, Christian Tovar
PDF file - 12K, Antitumor activity of RG7112 against a panel of solid tumor cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9c982ff418c10759c503fddf33cbb1
https://doi.org/10.1158/0008-5472.22398764.v1
https://doi.org/10.1158/0008-5472.22398764.v1
Autor:
Lyubomir T. Vassilev, Binh Vu, Peter Wovkulich, Frank Podlaski, Michael Linn, Kwong-Him To, Kenneth Kolinsky, Edmund Lee, Rosario Garrido, Christine Tardell, Brian Higgins Mingxuan Xia, Zoran Filipovic, Kathryn Packman, Bradford Graves, Christian Tovar
PDF file - 1272K, Comparison of MDM2 binding properties of RG7112 and nutlin-3a (S1); Overlay of the crystal structures of MDM2 bound to RG7112 and Nutlin-2 (S2); RG7112 is a non-genotoxic p53 activator (S3); Effect of RG7112 on the viability of HCT1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed0ac5a589251b018ba5a026af7a98e
https://doi.org/10.1158/0008-5472.22398770
https://doi.org/10.1158/0008-5472.22398770
Autor:
Lyubomir T. Vassilev, Binh Vu, Peter Wovkulich, Frank Podlaski, Michael Linn, Kwong-Him To, Kenneth Kolinsky, Edmund Lee, Rosario Garrido, Christine Tardell, Brian Higgins Mingxuan Xia, Zoran Filipovic, Kathryn Packman, Bradford Graves, Christian Tovar
PDF file - 136K, Includes HTRF, cell growth/viability, apoptosis assays and biacore, crystal structure and animal studies. Also includes supplemental references.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462335161b3d3a7a48af64749143adb9
https://doi.org/10.1158/0008-5472.22398767.v1
https://doi.org/10.1158/0008-5472.22398767.v1
Autor:
Cheryl Janson, Martin Weisel, Barry Goggin, Liang Weiling, Adrian J. Fretland, Robert Francis Kester, Christine Lukacs, Edmund Lee, Jennifer Lo, J. Heather Hogg, Xiaochun Han, Kyoungja Hong, Stacy Remiszewski, Shirley Li, Ann Polonskaia, John Anthony Moliterni, Kang Le, Lin Gao, Nam T. Le, Christophe Michoud, A. Schutt, Shahid Tannu, Andrew F. Donnell, Shaoqing Chen, Louis J. Lombardo, Steven Gregory Mischke, Mark T. Dvorozniak, Yan Lou, Christine Tardell, Kenneth Carey Rupert, Doug Aguilar, Dave S. Solis
Publikováno v:
Journal of medicinal chemistry. 56(20)
The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54996c22c1d8fb8749b427ec42349aeb
https://pubmed.ncbi.nlm.nih.gov/24093940
https://pubmed.ncbi.nlm.nih.gov/24093940
Autor:
Edmund Lee, Frank John Podlaski, Mingxuan Xia, Zoran Filipovic, Christian Tovar, Bradford Graves, Peter Michael Wovkulich, Rosario Garrido, Kwong-Him To, Christine Tardell, Kenneth Kolinsky, Lyubomir T. Vassilev, Brian Higgins, Michael Linn, Binh Thanh Vu, Packman Kathryn E
Publikováno v:
Cancer research. 73(8)
MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6e06251d7077c0ea5ca6f9d861db710
https://pubmed.ncbi.nlm.nih.gov/23400593
https://pubmed.ncbi.nlm.nih.gov/23400593
Autor:
Brian P. Higgins, Christine Tardell, Brenden Chen, Boylan John Frederick, Packman Kathryn E, Huifeng Niu
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42598 (2012)
PLoS ONE
PLoS ONE
Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84df8eb35f6858cd60991b58694c083
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22880048/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22880048/?tool=EBI
Autor:
Brian Higgins, Markus Thomas, Annette Seidl, Chandra Pamulapati, Alvin S. Stern, Packman Kathryn E, Silke Hansen, Ying Li, Huifeng Niu, Kuo-Sen Huang, David C. Heimbrook, Windy Berkofsky-Fessler, Sherif Daouti, Julie Hang, Olaf Mundigl, Debra Lucas-McGady, James Cai, Zoran Filipovic, Xiaolei Zhang, Holly Hilton, Ueli Gubler, Gennady Samokhin, Christine Tardell
Publikováno v:
Cancer Research. 72:4827-4827
Hepsin is overexpressed in prostate and other cancers where it is implicated in promoting tumor growth, invasion, and metastasis. To further our understanding of the role of hepsin in prostate and breast cancer, a fully humanized monoclonal antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8e59ea379adae5b7c2418c979b290ca
https://doi.org/10.1158/1538-7445.am2012-4827
https://doi.org/10.1158/1538-7445.am2012-4827
Autor:
John Frederick Boylan, Huifeng Niu, Christine Tardell, Brenden Chen, Packman Kathryn E, Brian Higgins
Publikováno v:
Molecular Cancer Therapeutics. 10:B130-B130
The BRAFV600E mutation is frequently found in human cancers (∼ 8%), with the highest incidence in melanoma (60–70%). Small molecules targeting BRAFV600E or MEK have shown significant clinical activity in melanoma patients carrying the BRAFV600E m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7c13d2df9dfe9fdea0c519df4d67fc0
https://doi.org/10.1158/1535-7163.targ-11-b130
https://doi.org/10.1158/1535-7163.targ-11-b130